Tobevibart clinical trials
Also written VIR-3434.
How each study uses tobevibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tobevibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Vir Biotechnology, Inc. (8) · Virion Therapeutics (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test tobevibart, phase 3 first.
- Dec 2026A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePhase 3 · Vir Biotechnology, Inc.
- Nov 2026A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPhase 2 · Vir Biotechnology, Inc.
Studies
Open first, then newest update. How each study uses tobevibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]RecruitingPhase 2University Health Network, TorontoNCT06216470Written as VIR-3434
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionActive, not recruitingPhase 3Vir Biotechnology, Inc.NCT06903338Written as Tobevibart
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434CompletedPhase 1Vir Biotechnology, Inc.NCT05484206Written as VIR-3434
- Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide TherapyCompletedPhase 1Virion TherapeuticsNCT06070051Written as VIR-3434
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideActive, not recruitingPhase 3Vir Biotechnology, Inc.NCT07128550Written as Tobevibart
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Active, not recruitingPhase 2Vir Biotechnology, Inc.NCT05461170Written as VIR-3434
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionCompletedPhase 2Vir Biotechnology, Inc.NCT04856085Written as VIR-3434
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionCompletedPhase 1/2Vir Biotechnology, Inc.NCT05612581Written as VIR-3434
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionActive, not recruitingPhase 2Vir Biotechnology, Inc.NCT07142811Written as Tobevibart
- Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionCompletedPhase 1Vir Biotechnology, Inc.NCT04423393Written as VIR-3434
Codes
What other systems call tobevibart · ClinicalTrials.gg INT017595
- UNII (FDA) PL93ZHC4L3TOBEVIBARTOne source FDA
- NCI Thesaurus C190476TobevibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PL93ZHC4L3 | TOBEVIBART | One source FDA |
| NCI Thesaurus | C190476 | Tobevibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.